Table 2.
Screening Sensitivity Differences between Models a
| Model | Stage I Sensitivity | Stage II Sensitivity | Stage III Sensitivity | Stage IV Sensitivity |
|---|---|---|---|---|
| MISCAN | 40.3% | 43.9% | 71.3% | 98.0% |
| UoM/BCC | 31.3% | 35.1% | 62.7% | 87.1% |
| LCOS | 52.1% | 61.8% | 92.2% | 92.6% |
| LCPM | 43.5% | 67.0% | 90.2% | 86.4% |
| Oncosim | 91.5% | 90.8% | 91.2% | 91.4% |
| Median | 43.5% | 61.8% | 90.2% | 91.4% |
LCOS, Lung Cancer Outcomes Simulation model; LCPM, Lung Cancer Policy Model; MISCAN, Microsimulation Screening Analysis model; UoM/BCC, Lung Cancer Natural History and Screening model.
a
At the time of the analysis, Oncosim’s assumed screening sensitivity depends on screening round and age group and did not explicitly model stage-specific sensitivities. Rather, it assigns a stage to a clinically detected cancer consistent with national cancer registry data (by sex, age group, and jurisdiction) and a stage to a screen-detected cancer upon the moment of detection that is consistent with the National Lung Screening Trial results.